🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 14/01/1997 | 23,75 | 23,88 | 22,56 | 22,63 | -4,74% | 5,53% | 1.397.800 |
| 13/01/1997 | 23,13 | 24,25 | 22,81 | 23,75 | +3,26% | 6,22% | 650.000 |
| 10/01/1997 | 21,75 | 23,75 | 21,75 | 23,00 | +4,55% | 9,20% | 1.194.600 |
| 09/01/1997 | 22,88 | 23,25 | 21,63 | 22,00 | -2,49% | 7,10% | 347.000 |
| 08/01/1997 | 22,19 | 23,00 | 22,19 | 22,56 | +4,03% | 3,66% | 1.695.200 |
| 07/01/1997 | 20,63 | 21,75 | 20,63 | 21,69 | +5,15% | 5,45% | 2.268.400 |
| 06/01/1997 | 19,19 | 21,00 | 19,13 | 20,63 | +7,49% | 9,77% | 1.396.400 |
| 03/01/1997 | 19,25 | 19,38 | 18,88 | 19,19 | +0,33% | 2,60% | 229.000 |
| 02/01/1997 | 18,88 | 19,88 | 18,88 | 19,13 | -4,97% | 5,30% | 646.200 |
| 31/12/1996 | 19,75 | 21,13 | 19,38 | 20,13 | +4,55% | 8,86% | 1.198.000 |
| 30/12/1996 | 18,50 | 19,25 | 18,25 | 19,25 | +4,76% | 5,41% | 225.400 |
| 27/12/1996 | 18,00 | 18,50 | 18,00 | 18,38 | +1,38% | 2,78% | 238.600 |
| 26/12/1996 | 17,56 | 18,38 | 17,50 | 18,13 | +5,07% | 4,98% | 209.000 |
| 24/12/1996 | 17,25 | 17,56 | 17,25 | 17,25 | -0,72% | 1,81% | 231.000 |
| 23/12/1996 | 18,13 | 18,13 | 17,13 | 17,38 | -3,14% | 5,52% | 299.600 |
| 20/12/1996 | 17,38 | 18,13 | 17,00 | 17,94 | +2,50% | 6,47% | 1.548.600 |
| 19/12/1996 | 15,88 | 17,88 | 15,88 | 17,50 | +10,24% | 12,60% | 940.000 |
| 18/12/1996 | 15,38 | 16,00 | 15,25 | 15,88 | +5,83% | 4,88% | 265.200 |
| 17/12/1996 | 15,38 | 15,56 | 15,00 | 15,00 | -2,44% | 3,66% | 98.800 |
| 16/12/1996 | 15,25 | 15,63 | 14,88 | 15,38 | +3,36% | 4,92% | 270.200 |
| 13/12/1996 | 15,00 | 15,50 | 14,38 | 14,88 | -2,46% | 7,50% | 427.000 |
| 12/12/1996 | 16,13 | 16,13 | 15,00 | 15,25 | -4,31% | 6,98% | 195.000 |
| 11/12/1996 | 15,88 | 16,25 | 15,63 | 15,94 | -1,16% | 3,94% | 214.600 |
| 10/12/1996 | 16,38 | 16,94 | 16,13 | 16,13 | -1,15% | 4,96% | 349.800 |
| 09/12/1996 | 16,63 | 16,63 | 15,88 | 16,31 | -0,38% | 4,51% | 145.000 |
| 06/12/1996 | 15,25 | 16,75 | 15,25 | 16,38 | +3,97% | 9,84% | 354.600 |
| 05/12/1996 | 15,63 | 16,25 | 15,63 | 15,75 | -0,79% | 4,00% | 131.800 |
| 04/12/1996 | 15,50 | 15,88 | 15,25 | 15,88 | +2,42% | 4,03% | 313.200 |
| 03/12/1996 | 16,00 | 16,38 | 15,38 | 15,50 | -1,64% | 6,25% | 401.000 |
| 02/12/1996 | 15,88 | 16,31 | 15,75 | 15,76 | -2,28% | 3,54% | 132.000 |